Thermo Fisher Scientific (TMO) PT Raised to $320.00 at BTIG Research

Share on StockTwits

Thermo Fisher Scientific (NYSE:TMO) had its target price raised by BTIG Research to $320.00 in a research note issued to investors on Thursday, The Fly reports. They currently have a buy rating on the medical research company’s stock.

Several other research analysts have also issued reports on TMO. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an outperform rating in a research report on Wednesday, January 30th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a hold rating to a buy rating and set a $299.00 price target on the stock in a research report on Wednesday, May 15th. UBS Group lifted their price target on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a buy rating in a research report on Thursday. Deutsche Bank lifted their price target on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a buy rating in a research report on Friday, March 22nd. Finally, Argus lifted their price target on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a buy rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $295.92.

Shares of NYSE:TMO opened at $271.02 on Thursday. The company has a current ratio of 1.69, a quick ratio of 1.16 and a debt-to-equity ratio of 0.61. The company has a market cap of $106.14 billion, a P/E ratio of 24.37, a PEG ratio of 1.74 and a beta of 1.11. Thermo Fisher Scientific has a 12 month low of $202.83 and a 12 month high of $282.98.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.07. The firm had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.04 billion. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.50 earnings per share. As a group, analysts anticipate that Thermo Fisher Scientific will post 12.2 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 16th. Shareholders of record on Friday, June 14th will be given a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 6.83%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,713 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the transaction, the chief executive officer now directly owns 302,193 shares in the company, valued at approximately $82,562,149.53. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Gregory J. Herrema sold 19,808 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $253.29, for a total transaction of $5,017,168.32. Following the transaction, the senior vice president now owns 25,688 shares in the company, valued at $6,506,513.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 76,320 shares of company stock worth $20,405,269. Corporate insiders own 0.45% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Financial Planning LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $27,000. Hanson McClain Inc. grew its holdings in shares of Thermo Fisher Scientific by 263.9% during the 4th quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares in the last quarter. Truvestments Capital LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $29,000. Capital Investment Advisory Services LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $35,000. Finally, Liberty Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 88.43% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Bear Market

The Fly

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect IBERIABANK Corp  Will Announce Quarterly Sales of $312.20 Million
Zacks: Analysts Expect IBERIABANK Corp Will Announce Quarterly Sales of $312.20 Million
Zacks: Brokerages Anticipate Ball Co.  Will Post Quarterly Sales of $3.03 Billion
Zacks: Brokerages Anticipate Ball Co. Will Post Quarterly Sales of $3.03 Billion
$40.49 Million in Sales Expected for Radius Health Inc  This Quarter
$40.49 Million in Sales Expected for Radius Health Inc This Quarter
A. O. Smith Corp  Expected to Announce Quarterly Sales of $821.43 Million
A. O. Smith Corp Expected to Announce Quarterly Sales of $821.43 Million
Zacks: Brokerages Anticipate Align Technology, Inc.  Will Post Quarterly Sales of $595.61 Million
Zacks: Brokerages Anticipate Align Technology, Inc. Will Post Quarterly Sales of $595.61 Million
Universal Forest Products, Inc.  Expected to Post Quarterly Sales of $1.24 Billion
Universal Forest Products, Inc. Expected to Post Quarterly Sales of $1.24 Billion


© 2006-2019 Ticker Report